{"entity":{"id":"avc-201","kind":"drug","name":"AVC-201","aka":["Allo-RevCAR01-T-CD123","Allo-RevCAR01-T with R-TM123"],"tldr":"AVC-201 is an experimental allogeneic CRISPR-engineered switchable CAR-T cell therapy from AvenCell Therapeutics, in phase 1 trials for CD123-positive relapsed/refractory or MRD-positive acute myeloid leukaemia.","summary":"AVC-201 (Allo-RevCAR01-T-CD123, Allo-RevCAR01-T with R-TM123) is an allogeneic CRISPR-engineered switchable CAR-T cell therapy (RevCAR, with separately dosed targeting module) from AvenCell Therapeutics, with Intellia Therapeutics as partner. Donor T cells, gene-edited with CRISPR to avoid graft-versus-host disease and rejection, carrying a switchable receptor activated only by a separately infused CD123 targeting module, so activity can be switched off and on. Its furthest stage is phase 1, for CD123-positive relapsed/refractory or MRD-positive acute myeloid leukaemia. ClinicalTrials.gov registers it in one study linked below. Phase 1a portion of RevSTAR-123 completed; results presented as an EHA 2026 late-breaking plenary oral (company release 2 June 2026). Registry status recruiting. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"AvenCell Therapeutics: avencell.com","url":"https://avencell.com/pipeline/"},{"label":"AvenCell Therapeutics: avencell.com","url":"https://avencell.com/avencell-therapeutics-to-report-phase-1a-results-of-first-in-class-switchable-allogeneic-cd123-car-t-therapy-for-aml-in-late-breaking-oral-presentation-at-eha-2026/"},{"label":"AvenCell Therapeutics: avencell.com","url":"https://avencell.com/avencell-therapeutics-to-report-phase-1a-results-of-first-in-class-switchable-allogeneic-cd123-car-t-therapy-for-aml-in-late-breaking-oral-presentation-at-eha-2026/"},{"label":"AvenCell Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/study/NCT05949125"},{"label":"ClinicalTrials.gov: trials of AVC-201","url":"https://clinicaltrials.gov/search?intr=AVC-201"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":["cd123"],"drugs":[],"companies":["avencell-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05949125"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"AVC-201","modality":"Allogeneic CRISPR-engineered switchable CAR-T cell therapy (RevCAR, with separately dosed targeting module)","mechanism":"Donor T cells, gene-edited with CRISPR to avoid graft-versus-host disease and rejection, carrying a switchable receptor activated only by a separately infused CD123 targeting module, so activity can be switched off and on.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/avc-201/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"target":[{"id":"cd123","kind":"target","name":"CD123","route":"/targets/cd123/"}],"company":[{"id":"avencell-therapeutics","kind":"company","name":"AvenCell Therapeutics","route":"/companies/avencell-therapeutics/"}],"trial":[{"id":"nct05949125","kind":"trial","name":"Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion)","route":"/trials/nct05949125/"}]}}